Galapagos to advance filgotinib to Phase 3 in rheumatoid arthritis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- Wall St falls as Trump's Iran remarks rattle investors; Broadcom gains
- Oil prices jump 7% as US-Iran truce buckles under fresh hostilities
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- GameStop stockholders approve share count increase to 2.5 billion
Credit Suisse Downgrades Galapagos NV (GLPG) to Neutral
September 28, 2015 6:48 AM EDTCredit Suisse downgraded Galapagos NV (NASDAQ: GLPG) from Outperform to Neutral and cuts its price target from EUR62 to EUR46.
Analyst V. Divan commented, "BBV's decision to opt-out of filgotinib and advance ABT-494 into phase 3 can potentially be... More
Cowen Remains Bullish on Galapagos NV (GLPG) After AbbVie (ABBV) Declined to Opt-In for Phase III Development of Filgotinib
September 25, 2015 3:14 PM EDTCowen maintained an Outperform rating on Galapagos NV (NASDAQ: GLPG) following AbbVie's (NYSE: ABBV) decision to terminate its agreement for JAK1 inhibitor filgotinib. The decision was in conjunction with the release of positive data from ABT-494's (JAK1... More
Galapagos NV (GLPG) to Advance Filgotinib to Phase 3 in Rheumatoid Arthritis
September 25, 2015 10:51 AM EDTGalapagos NV (NASDAQ: GLPG) announced today that the Company will be moving filgotinib, its highly selective JAK1 inhibitor, into Phase 3 in rheumatoid arthritis by early 2016. Filgotinib has shown best-in-class efficacy and safety in the DARWIN Phase 2B studies in rheumatoid arthritis and is now fully owned... More
